Zenosense,
and co-developer partner, Sgenia Group, Madrid, are engaged in the design and
creation of a cost-effective methicillin-resistant staphylococcus aureus (MRSA)
detector system vital to battling what has been called a multi-billion problem.
The Sgenia Group has established Zenon Biosystem, a dedicated subsidiary
contracted to develop the MRSA device for Zenosense. The product is expected to
appeal to distributor channels and end users due to increasing demand for an
economical detection solution.
Methicillin-resistant
Staphylococcus aureus (MRSA) infection is caused by a strain of staph bacteria
that has become resistant to the antibiotics used to treat ordinary staph
infections. Most MRSA infections occur in people who have been in hospitals or
other health care environments, such as nursing homes and dialysis centers.
When it occurs in these settings, it is known as health care-associated MRSA
(HA-MRSA). HA-MRSA infections typically are associated with invasive procedures
or devices, such as surgeries, intravenous tubing or artificial joints.
Another
type of MRSA infection has occurred in the wider community of healthy people.
This form, referred to as community-associated MRSA (CA-MRSA), often surfaces
as a skin boil. It’s spread by skin-to-skin contact. At-risk populations are
groups such as high school wrestlers, child care workers and people who live in
crowded conditions.
MRSA can
be treated or avoided altogether, but the key is timely identification. Known
as a superbug, the infection brings with it a substantial financial price tag
for private and public health care systems across the country and elsewhere
however early detection is necessary for protective measures to be put into
place.
An
“electronic nose” device currently exists to detect bacteria from cultures.
However, these devices are physically bulky and cost prohibitive to install on
larger scales. There is no cost-effective system available for detecting MRSA
infection early in the patient or in environments where it is known to be contracted.
ZENO’s plan is to situate a detector on a special sensor that Sgenia has
already developed. Once installed, it can detect the Volatile Organic Compounds
(VOCs) signature emitted by MRSA. The MRSA VOC signature is only emitted when
the bacteria has infected and expressed itself as a disease in the patient, and
can be detected prior to the patient developing symptoms, which would aid in
earlier intervention.
For more
information, visit www.zenosense.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment